{
  "id": "graft-versus-host-disease",
  "title": "Graft-versus-Host Disease",
  "lang": "en",
  "source_lang": "en",
  "summary": "Graft-versus-host disease is an immune complication in which donor-derived cells attack recipient tissues, chiefly after allogeneic hematopoietic transplantation.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "GVHD",
    "Graft-vs-host disease",
    "Graft versus host disease"
  ],
  "generated_at": "2026-11-02",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/graft-versus-host-disease/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/graft-versus-host-disease/",
      "json": "https://aiwiki.page/zh/graft-versus-host-disease.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Graft-versus-host disease (GVHD) is a disorder in which immunologically active cells transferred from a donor recognize the recipient’s tissues as foreign and cause tissue injury. It occurs principally after allogeneic hematopoietic stem cell transplantation, a procedure used to treat leukemia, lymphoma, aplastic anemia, and other blood or immune disorders. Less commonly, it follows the transfusion of cellular blood components or transplantation of an organ containing substantial numbers of donor lymphocytes. Unlike transplant rejection, in which the recipient’s immune system attacks a graft, GVHD proceeds in the opposite immunological direction.\n\nGVHD comprises acute and chronic forms distinguished primarily by their clinical manifestations rather than simply by time since transplantation. Acute GVHD mainly affects the skin, gastrointestinal tract, and liver. Chronic GVHD can involve numerous organs and combines immune dysregulation, inflammation, and tissue scarring. Both forms can cause substantial illness, disability, and death, while their treatment increases susceptibility to infection. The central biological challenge is to control harmful donor immune responses without eliminating protection against pathogens or the beneficial donor immune activity directed against residual malignant cells."
    },
    {
      "heading": "Definition, historical development, and classification",
      "text": "The essential requirements for GVHD were articulated by the transplantation immunologist Rupert Billingham in 1966: the graft must contain immunologically competent cells; the recipient must possess antigens absent from the donor; and the recipient must be unable to eliminate the transferred cells effectively. These principles explained experimental “runt disease” in animals and the human disorder that became increasingly recognizable as bone marrow transplantation developed. The relevant donor cells are principally T cells, although other immune populations contribute importantly, especially in chronic disease. In hematopoietic transplantation, donor-derived immune cells can persist and continually regenerate, giving GVHD a different biological setting from a short-lived exposure to foreign cells.\n\nHistorically, acute GVHD was defined as disease arising within 100 days of transplantation, whereas disease after day 100 was labeled chronic. That distinction proved inadequate because reduced-intensity conditioning, donor lymphocyte infusions, and changes in immune suppression could produce acute-type manifestations much later. Conversely, characteristic chronic manifestations could appear before day 100. The US National Institutes of Health consensus framework introduced in 2005 and revised in 2014 therefore emphasized clinical phenotype. Classic acute GVHD occurs within the first 100 days without diagnostic chronic features. Persistent, recurrent, or late-onset acute GVHD occurs after day 100 but retains acute manifestations.\n\nChronic GVHD includes a classic form, with characteristic chronic manifestations and no acute features, and an overlap form, in which chronic and acute manifestations coexist. For example, a recipient with sclerotic skin disease and inflammatory diarrhea may have overlap chronic GVHD rather than a disorder classifiable solely by transplantation date. Acute GVHD severity is commonly expressed through organ stages and an overall grade, whereas chronic GVHD uses organ-specific scores and an overall mild, moderate, or severe category. These classifications serve different purposes and are not interchangeable.\n\nGVHD is also classified by the setting in which donor lymphocytes are transferred. Transfusion-associated GVHD usually appears within several weeks of a blood transfusion and characteristically includes profound marrow failure. GVHD after solid-organ transplantation is rare but recognized particularly after liver or intestinal transplantation, where the graft carries donor lymphocytes. Autologous transplantation, in which a patient receives their own cells, does not create the usual donor–recipient genetic mismatch; syndromes described as autologous GVHD or GVHD-like disease therefore require separate interpretation rather than automatic equivalence with conventional allogeneic GVHD."
    },
    {
      "heading": "Immunological mechanisms and tissue injury",
      "text": "The initiating event in acute GVHD is often injury caused by the transplant conditioning regimen, which may include chemotherapy and radiation therapy. Damaged tissues release danger signals, while disruption of intestinal barriers allows microbial products to reach immune cells. These signals activate antigen-presenting cells and promote the release of inflammatory mediators. Donor T cells subsequently encounter recipient antigens in an environment favoring activation rather than tolerance. Conditioning injury is not an absolute requirement in every clinical setting, but it is an important amplifier of the inflammatory process in conventional transplantation.\n\nRecognition depends heavily on human leukocyte antigen (HLA) molecules, which display peptide fragments to T cells. A major HLA mismatch can generate a strong donor immune response, but GVHD can also develop between HLA-matched siblings. In that setting, genetically variable proteins produce minor histocompatibility antigens that differ between donor and recipient. Some are expressed broadly, whereas others are concentrated in blood-forming cells. Activated donor T cells expand, migrate into target tissues, and cause injury through cytotoxic pathways, including perforin–granzyme release and death-receptor signaling. Cytokines such as tumor necrosis factor, interferon gamma, and several interleukins sustain recruitment and tissue damage.\n\nThe intestine is both a target and an amplifier of disease. Damage to intestinal stem cells and epithelial cells impairs regeneration and weakens the mucosal barrier. Changes in the gut microbiome, partly related to antibiotics, diet, conditioning, and inflammation, can further alter immune regulation. Reduced microbial diversity and domination by particular bacterial groups have been associated with adverse transplantation outcomes, although association does not establish that a specific microbial pattern directly causes GVHD. Experimental and clinical research therefore distinguishes biological plausibility from evidence that modifying the microbiome improves survival.\n\nChronic GVHD involves a broader failure of immune tolerance. Injury to the thymus can interfere with the development of a properly selected T-cell repertoire, while impaired regulatory T-cell function reduces control of self-reactive and alloreactive responses. Abnormal B-cell activation, altered antibody production, macrophage signaling, and fibroblast activation contribute to persistent inflammation and fibrosis. Chronic disease can consequently resemble features of autoimmune diseases without being identical to them. The balance between active inflammation and established structural damage varies by organ and helps explain why suppressing immune activity does not necessarily reverse scarring, contractures, or fixed airflow obstruction."
    },
    {
      "heading": "Frequency, risk factors, and transplantation context",
      "text": "GVHD frequency varies substantially with the population studied, graft source, donor relationship, HLA matching, conditioning regimen, preventive treatment, and diagnostic criteria. Across many allogeneic transplantation settings, grade II–IV acute GVHD has historically affected roughly 30–50% of recipients, while chronic GVHD has affected approximately 30–50% of longer-term survivors. These are broad contextual ranges rather than universal rates. Modern prophylaxis can produce substantially different results, and comparisons are misleading if they combine all grades of disease, different observation periods, or different proportions of high-risk recipients. Incidence also depends on competing events: patients who die early or experience early malignant relapse may never remain at risk long enough to develop chronic GVHD.\n\nHLA disparity is a major risk factor, but its effect depends on the preventive platform. Haploidentical transplantation, in which donor and recipient share one inherited HLA haplotype, has become widely feasible through approaches such as post-transplantation cyclophosphamide. Unrelated donors can also be used successfully with close HLA matching and appropriate prophylaxis. Donor age, recipient age, conditioning intensity, and aspects of donor–recipient sex and reproductive history can influence risk. A female donor who has previously been pregnant may carry immune memory against antigens encountered during pregnancy, contributing in some settings to increased alloreactivity.\n\nThe cellular source of the graft is particularly relevant to chronic disease. Peripheral blood stem-cell grafts generally contain more T cells than bone marrow grafts and have often been associated with a higher risk of chronic GVHD. Bone marrow may therefore offer a chronic-GVHD advantage in some settings, although graft selection also considers engraftment, disease control, donor factors, and the preventive regimen. Umbilical cord blood transplantation has distinct patterns of immune recovery and alloreactivity, and its outcomes cannot be predicted simply by applying risk estimates from adult-donor transplantation.\n\nPrevious acute GVHD is a recognized risk factor for chronic GVHD, but chronic disease can develop without a documented acute episode. Donor lymphocyte infusion, sometimes used to strengthen donor immune activity against recurrent malignancy, can provoke either form. The therapeutic context matters because donor alloreactivity is not uniformly harmful: the graft-versus-leukemia effect can reduce malignant relapse. GVHD and antitumor immunity overlap biologically but are not inseparable. Prevention studies consequently assess relapse, infections, graft failure, and survival alongside GVHD frequency, rather than treating the lowest possible GVHD rate as sufficient evidence of the best overall transplant strategy."
    },
    {
      "heading": "Acute clinical manifestations and severity grading",
      "text": "The skin is frequently the first clinically apparent target of acute GVHD. A maculopapular rash may begin on the face, ears, palms, soles, or trunk and then spread. Mild disease can resemble a drug eruption or viral exanthem. Severe disease produces generalized redness, blistering, and epidermal separation, creating extensive barrier loss. Skin staging reflects the percentage of body surface involved and, at the most severe stage, extensive skin injury with blistering or desquamation. The appearance is not sufficiently specific to establish the diagnosis by itself, particularly when recipients are exposed to multiple medications and infectious risks.\n\nGastrointestinal involvement ranges from anorexia, persistent nausea, and vomiting to profuse watery diarrhea, cramping, bleeding, and ileus. Upper gastrointestinal disease may be clinically important even without substantial diarrhea. Lower gastrointestinal disease can cause major fluid and protein losses, malabsorption, and severe abdominal pain. Diarrheal volume is used in conventional staging, with age- and size-appropriate interpretation in children. Severe abdominal pain, ileus, or grossly bloody stool can indicate advanced disease even when measured stool volume is not striking. Damage to the intestinal barrier also increases the risk of bloodstream infection.\n\nLiver involvement most often produces a cholestatic pattern, including rising bilirubin and alkaline phosphatase, although a hepatitic pattern with marked aminotransferase elevation can occur. Jaundice may become evident in more severe disease. Because transplant recipients have many potential causes of liver dysfunction—including medication toxicity, viral infection, sepsis, and sinusoidal obstruction syndrome—abnormal liver tests alone do not establish GVHD. Classical acute liver staging is based primarily on bilirubin concentration, but clinical interpretation considers the entire biochemical and transplantation context.\n\nOverall acute GVHD grades usually range from I to IV and combine the severity of skin, liver, and gastrointestinal involvement. Grade I generally denotes limited disease, often confined to skin, whereas grade IV represents life-threatening involvement. The modified Glucksberg system and the Mount Sinai Acute GVHD International Consortium, or MAGIC, criteria are widely used approaches to standardizing assessment. Organ stage is not the same as overall grade: a patient’s final grade depends on the pattern across organs. Severity at presentation and subsequent response to treatment both carry prognostic information. Steroid-refractory lower gastrointestinal or liver disease is particularly concerning, but the course cannot be inferred from a single symptom or laboratory value in isolation."
    },
    {
      "heading": "Chronic manifestations and organ scoring",
      "text": "Chronic GVHD often produces recognizable changes in the skin and associated tissues. Lichen planus-like lesions are characterized by inflammatory, often violaceous changes, while sclerotic disease causes skin thickening, tightness, and reduced mobility. Deeper involvement can affect subcutaneous tissues and fascia, leading to joint contractures and restricted chest-wall movement. Pigment changes, hair loss, and nail abnormalities can occur but are less specific. Some findings reflect active immune injury; others represent persistent damage after inflammation has subsided. This distinction is essential because a limitation in movement may remain even when the inflammatory component responds to therapy.\n\nThe mouth may develop lichen planus-like white changes, erythema, ulcers, sensitivity, and reduced salivary function. Salivary gland dysfunction can increase the risk of dental caries and oral infection. Ocular disease commonly affects tear production and the ocular surface, producing dryness, grittiness, light sensitivity, and visual disturbance; severe cases can damage the cornea. Genital involvement may cause inflammatory lesions, scarring, adhesions, or narrowing. These manifestations can substantially affect eating, vision, sexual function, and daily activities even when they do not immediately threaten survival.\n\nPulmonary chronic GVHD is most characteristically associated with bronchiolitis obliterans syndrome, a small-airway disorder producing airflow obstruction. Early disease may be detected through declining lung function before prominent symptoms appear. Later features include exertional breathlessness, cough, and reduced exercise capacity. Evaluation uses serial spirometry, imaging, and assessment for infection or other causes of obstruction. Gastrointestinal and hepatic manifestations can coexist with chronic disease, but diarrhea or abnormal liver tests are not independently diagnostic of chronic GVHD because they overlap with acute GVHD and numerous other transplant complications.\n\nThe NIH organ scoring system generally assigns scores from 0 to 3 to involved sites, including skin, mouth, eyes, gastrointestinal tract, liver, lungs, joints and fascia, and genital tract. Overall mild disease typically involves one or two organs with only score-1 impairment and no lung involvement. Moderate disease includes broader mild involvement, a score of 2 in an organ, or mild lung involvement. Severe disease includes a score of 3 in an organ or more substantial lung impairment. Attribution remains important: an abnormality due entirely to another condition should not be counted as GVHD. Scoring also has limitations, because it can combine active disease and irreversible damage and may not fully capture fatigue, symptom burden, or the practical consequences of several simultaneous mild impairments."
    },
    {
      "heading": "Diagnostic evaluation and biomarkers",
      "text": "GVHD is a clinical diagnosis supported, when appropriate, by tissue examination and exclusion of competing explanations. Assessment integrates transplant timing, donor and graft characteristics, preventive medications, recent drug changes, infections, examination findings, and organ-specific tests. A biopsy can strengthen diagnostic confidence, but a negative or nonspecific result does not always exclude disease. Sampling may miss patchy abnormalities, and prior treatment can change the appearance. Conversely, some microscopic features associated with GVHD can also occur with medications or infections. In severe presentations, diagnostic evaluation and treatment may proceed in parallel rather than awaiting a single definitive test.\n\nIn acute skin disease, histopathology may show injury at the interface between epidermis and dermis, apoptotic keratinocytes, and, in advanced cases, epidermal separation. Gastrointestinal biopsies can show epithelial apoptosis, crypt injury, crypt loss, and mucosal denudation. Endoscopic appearance can be deceptively mild despite microscopic disease. Evaluation of diarrhea also considers medication toxicity, conditioning-related injury, Clostridioides difficile infection, cytomegalovirus, and other pathogens. Liver biopsy may show small bile-duct epithelial injury and cholestasis, but bleeding risk, the likelihood of alternative diagnoses, and the effect of the result on management influence its use.\n\nChronic GVHD diagnosis follows a different logic from merely documenting persistent symptoms. The NIH framework distinguishes diagnostic manifestations, which can establish chronic GVHD in the appropriate setting, from distinctive manifestations that require additional evidence. Lichen planus-like changes and certain forms of sclerosis are examples of particularly characteristic findings. Dry eyes, weight loss, or abnormal liver enzymes alone are insufficiently specific. Functional tests, specialist examinations, imaging, and tissue sampling help establish organ involvement and distinguish chronic GVHD from infection, medication effects, recurrent malignancy, and unrelated disease.\n\nBlood-based biomarkers have advanced risk assessment but do not replace clinical diagnosis. ST2, the soluble form of an interleukin-33 receptor component, and REG3α, a protein associated with intestinal epithelial responses, are incorporated into the MAGIC algorithm probability. This algorithm estimates the risk of adverse outcomes, particularly nonrelapse mortality associated with acute GVHD, and can add information beyond clinical grade. Its most established role is prognostic rather than proof that GVHD is present. Biomarker thresholds, assay methods, sampling time, and treatment context affect interpretation. Chronic GVHD has no single broadly accepted blood test that independently establishes its diagnosis, and candidate markers must be evaluated against the diversity of organs and disease states involved."
    },
    {
      "heading": "Prevention and the balance of donor immunity",
      "text": "Prevention begins before transplantation with donor selection, HLA assessment, graft-source choice, and selection of a conditioning and immune-suppression strategy. Complete elimination of donor alloreactivity is not necessarily desirable because it can compromise engraftment, immune recovery, or antitumor effects. Preventive regimens therefore aim to reduce clinically important GVHD while preserving adequate donor immune function. The same regimen can have different consequences in a patient receiving a fully matched donor graft, a haploidentical graft, or a graft for a nonmalignant disorder, where there is no desired graft-versus-leukemia effect.\n\nConventional pharmacological prophylaxis often combines a calcineurin inhibitor, such as tacrolimus or ciclosporin, with methotrexate or mycophenolate mofetil. Calcineurin inhibition reduces T-cell activation by interfering with signaling needed for interleukin-2 production. Methotrexate inhibits proliferating cells and has immunomodulatory effects, while mycophenolate limits nucleotide synthesis in lymphocytes. Antithymocyte globulin can reduce donor or recipient T-cell activity and is incorporated into selected transplant platforms. These approaches differ in their effects on engraftment, viral reactivation, relapse, organ toxicity, and immune recovery; they are not simply interchangeable methods of lowering a single risk.\n\nPost-transplantation cyclophosphamide has become an important preventive strategy, initially associated particularly with haploidentical transplantation and subsequently used more broadly. Typically administered early after graft infusion, it acts on rapidly proliferating alloreactive lymphocytes and also reshapes regulatory and recovering immune populations. In the BMT CTN 1703 randomized trial, reported in 2023, a regimen combining post-transplantation cyclophosphamide, tacrolimus, and mycophenolate improved one-year GVHD-free, relapse-free survival compared with tacrolimus and methotrexate in the studied reduced-intensity peripheral blood transplantation setting. Estimated one-year rates were 52.7% and 34.9%, respectively. That composite outcome captured severe acute GVHD, chronic GVHD requiring systemic treatment, relapse or progression, and death, rather than any occurrence of GVHD.\n\nOther approaches include graft manipulation to remove selected T-cell populations and costimulation blockade. Abatacept, a CTLA-4–immunoglobulin fusion protein, blocks CD80/CD86-mediated T-cell costimulation and received US approval in 2021 for acute GVHD prophylaxis in specified unrelated-donor transplantation settings, in combination with other agents. Prevention of transfusion-associated GVHD relies on a separate measure: irradiation of appropriate cellular blood components to prevent transfused lymphocytes from proliferating. Routine leukocyte reduction does not reliably provide equivalent protection. Irradiating the blood component is distinct from irradiating the patient, and the need for this measure depends on the transfusion setting and recognized recipient or donor-related risks."
    },
    {
      "heading": "Treatment of acute disease",
      "text": "Treatment intensity is guided by organ involvement, overall severity, progression, and the probability that symptoms truly represent GVHD. Limited skin disease can often be managed with topical therapy while existing systemic prophylaxis is maintained or adjusted. Clinically significant gastrointestinal, liver, or extensive skin disease usually requires systemic corticosteroids. Prednisone or intravenous methylprednisolone is commonly used, with an initial prednisone-equivalent dose around 1–2 mg/kg per day in many protocols. This is a description of clinical practice rather than a universal regimen: dose, route, and subsequent taper vary with severity, absorption, response, and complications.\n\nResponse assessment is dynamic. Improvement in rash, stool volume, abdominal symptoms, bilirubin, and overall function is considered alongside new organ involvement. Progression after several days of adequate steroids or failure to improve after a longer predefined interval can qualify as steroid-refractory disease, although exact definitions vary across trials and protocols. Some patients respond initially but relapse during tapering, creating a steroid-dependent pattern. Prolonged exposure is associated with muscle weakness, hyperglycemia, bone loss, psychiatric effects, and infection. These consequences make response durability and the ability to reduce steroid exposure important outcomes beyond short-term symptom improvement.\n\nRuxolitinib, an inhibitor of Janus kinases 1 and 2, is an established treatment for steroid-refractory acute GVHD. By interfering with cytokine signaling, it affects several pathways involved in donor immune activation and tissue inflammation. In the REACH2 randomized controlled trial, published in 2020, the day-28 overall response rate was 62.3% with ruxolitinib and 39.4% with investigator-selected control therapy. Adverse effects include cytopenias and infectious complications, and a response at day 28 does not necessarily imply complete recovery or a survival benefit in every subgroup. Choice of subsequent therapy depends on prior treatment, organ dysfunction, infection status, and regulatory availability.\n\nOther approaches used in selected settings include extracorporeal photopheresis, antithymocyte globulin, additional cytokine-directed treatments, and mesenchymal stromal-cell products. In December 2024, the US Food and Drug Administration approved remestemcel-L for steroid-refractory acute GVHD in pediatric patients aged two months and older. Supportive treatment remains central regardless of the immune-directed agent: fluid and electrolyte losses, nutritional impairment, pain, mucosal injury, and opportunistic infections can independently become life-threatening. Trials of acute GVHD therapy increasingly assess durable response, cumulative steroid exposure, nonrelapse mortality, and survival rather than relying only on an early fall in clinical grade."
    },
    {
      "heading": "Treatment of chronic disease and functional impairment",
      "text": "Chronic GVHD treatment depends on the number of organs affected, disease activity, functional consequences, and the balance between inflammation and established damage. Localized disease may be treated with organ-directed approaches, including topical anti-inflammatory agents for skin or mouth and therapies addressing ocular surface disease. More extensive or functionally important disease commonly requires systemic corticosteroids, sometimes with another immunosuppressive agent. Treatment often extends over months or years. A central difficulty is that improvement in one organ may occur alongside progression in another, while symptoms may persist because of scarring even after immune activity declines.\n\nSeveral targeted drugs have expanded options after initial treatment failure. Ibrutinib inhibits Bruton tyrosine kinase and other signaling pathways relevant to B- and T-cell activity. Ruxolitinib has randomized evidence in glucocorticoid-refractory or glucocorticoid-dependent chronic GVHD: in the REACH3 trial, published in 2021, overall response at week 24 was 49.7%, compared with 25.6% for investigator-selected best available therapy. Belumosudil inhibits ROCK2, a kinase involved in inflammatory and fibrotic pathways, and is used after multiple prior systemic treatments in specified jurisdictions. Their evidence bases, adverse-effect profiles, age indications, and approved treatment sequences differ.\n\nAxatilimab, an antibody targeting the colony-stimulating factor 1 receptor, acts on monocyte and macrophage pathways implicated in chronic inflammation and fibrosis. It received US approval in 2024 for chronic GVHD after at least two prior systemic therapies in adults and pediatric patients weighing at least 40 kg. Extracorporeal photopheresis is another established option in selected patients: circulating leukocytes are collected, exposed outside the body to a photosensitizing agent and ultraviolet A light, and returned. Its immunological effects include changes in antigen presentation and immune regulation rather than simple removal of all pathogenic cells. Cross-trial comparisons among these therapies are limited by differences in organ involvement, prior treatments, response definitions, and follow-up.\n\nFunctional management is distinct from, but complementary to, immune suppression. Physical therapy and occupational therapy address restricted movement, weakness, contractures, and limitations in everyday activities. Pulmonary disease may require serial lung-function assessment and organ-specific treatment, while oral and ocular disease often requires specialist care. Nutritional impairment can arise from painful oral disease, swallowing difficulty, gastrointestinal involvement, or treatment-related metabolic changes. NIH response criteria and patient-reported outcome instruments help document different dimensions of treatment effect. A reduction in inflammatory lesions, improved joint movement, relief of symptoms, and successful steroid reduction are related but separate outcomes, and no single score fully represents them all."
    },
    {
      "heading": "Prognosis, long-term consequences, and research priorities",
      "text": "Prognosis varies widely. Mild acute skin GVHD may resolve without lasting organ impairment, while severe steroid-refractory gastrointestinal or liver disease can be fatal. Chronic GVHD may eventually become inactive and permit withdrawal of systemic treatment, but some patients require prolonged therapy or retain permanent organ damage. Nonrelapse mortality includes deaths from GVHD itself and from associated infections or treatment complications. Analyses must therefore distinguish malignant relapse from other causes of death and account for their competing risks. A treatment that reduces GVHD but substantially increases relapse or fatal infection may not improve overall survival.\n\nLong-term consequences arise from both disease and treatment. Chronic immune suppression increases susceptibility to viral, fungal, and bacterial infections, while impaired mucosal barriers create additional routes of entry. Corticosteroid exposure contributes to osteoporosis, muscle wasting, metabolic complications, cataracts, and avascular bone injury. Persistent oral chronic GVHD and prolonged immune dysfunction are associated with an increased risk of oral squamous cell carcinoma. Lung involvement can produce lasting respiratory disability, and sclerotic disease can limit mobility or self-care. These outcomes make organ function and quality of life indispensable measures of disease burden rather than secondary considerations.\n\nGVHD also complicates immune reconstitution after transplantation. Donor-derived blood formation may be well established while protection against particular pathogens remains incomplete. Vaccine responses can be impaired by ongoing immune suppression and active disease, so post-transplantation vaccination schedules are distinct from routine schedules in immunologically healthy populations. Fatigue, sleep disruption, pain, altered appearance, and limitations in work or education can persist alongside measurable organ abnormalities. Mental health and social functioning are therefore relevant components of long-term outcome assessment, without implying that these difficulties occur uniformly in all survivors.\n\nResearch seeks to separate protective donor immunity from tissue-damaging alloreactivity. Approaches under investigation include regulatory T-cell therapies, selective manipulation of donor lymphocyte populations, tissue-protective strategies, microbiome-directed interventions, and biomarker-guided treatment intensity. Important methodological questions remain: whether a marker predicts benefit from a particular therapy rather than merely a poor prognosis; how to distinguish active chronic inflammation from irreversible fibrosis; and how to measure meaningful improvement across organs with different response times. Clinical studies increasingly combine biological measurements with organ function, treatment burden, relapse, survival, and patient-reported symptoms, because a transient response in one compartment does not by itself establish durable control of the disease."
    }
  ],
  "links": [
    "hematopoietic-stem-cell-transplantation",
    "leukemia",
    "lymphoma",
    "aplastic-anemia",
    "transplant-rejection",
    "t-cell",
    "blood-transfusion",
    "organ-transplantation",
    "chemotherapy",
    "radiation-therapy",
    "human-leukocyte-antigen",
    "cytokine",
    "thymus",
    "regulatory-t-cell",
    "b-cell",
    "fibrosis",
    "autoimmune-disease",
    "incidence",
    "pregnancy",
    "bone-marrow",
    "graft-versus-leukemia-effect",
    "rash",
    "nausea",
    "diarrhea",
    "abdominal-pain",
    "dental-caries",
    "shortness-of-breath",
    "cough",
    "spirometry",
    "biopsy",
    "histopathology",
    "biomarker",
    "corticosteroid",
    "randomized-controlled-trial",
    "opportunistic-infection",
    "physical-therapy",
    "occupational-therapy",
    "nutrition",
    "patient-reported-outcome",
    "osteoporosis",
    "quality-of-life",
    "vaccine",
    "mental-health"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}